Bob Nelsen (Michael Kovac/Getty Images)

End­points ex­clu­sive: Bob Nelsen's Re­silience snags Flori­da CD­MO work­ing with the De­fense De­part­ment on Covid-19 an­ti­body

Re­silience has on­ly been in ex­is­tence for less than six months, but Bob Nelsen’s next-gen man­u­fac­tur­ing play has made plen­ty of moves short­ly af­ter de­but­ing with an $800 mil­lion launch round. Now, the biotech look­ing to change drug man­u­fac­tur­ing is pick­ing up a Flori­da CD­MO part­nered with the De­part­ment of De­fense on a Covid-19 an­ti­body.

Re­silience is ac­quir­ing CD­MO Ol­o­gy Bioser­vices in a deal that will add two man­u­fac­tur­ing sites to the bi­coastal biotech’s foot­print as well as a gov­ern­ment-backed mon­o­clon­al an­ti­body, a source close to the mat­ter said Mon­day. Fi­nan­cial terms of the deal were not avail­able.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.